Doximity vs Omnicell
Omnicell reported revenue of $1.2 billion in fiscal 2025, 1.8 times Doximity's $645 million in fiscal 2026. Doximity's revenue grew 13.1% in its latest year, and Omnicell's grew 6.5%. Doximity had an operating margin of 33.3%, against 0.4% at Omnicell. Free cash flow was $326 million at Doximity and $87 million at Omnicell. Their fiscal years end in different months (March 31 and December 31), so the periods don't line up exactly.
Side by side
| Doximity | Omnicell | |
|---|---|---|
| Latest fiscal year | FY2026, Mar 31, 2026 | FY2025, Dec 31, 2025 |
| Revenue | $645M | $1.2B |
| Revenue growth | 13.1% | 6.5% |
| Revenue growth a year, last 5 years | 25.5% | 5.8% |
| Gross margin | 89.1% | 42.5% |
| Operating margin | 33.3% | 0.4% |
| Net margin | 30.4% | 0.2% |
| Free cash flow | $326M | $87M |
| Free cash flow margin | 50.6% | 7.3% |
| Return on capital | 91.3% | 0.2% |
| Net debt to EBITDA | −3.3x | −0.3x |
| Dividends and buybacks | $432M | $78M |
| Change in diluted share count | −1.1% | 0.2% |
| Last close | $32.51 | $37.34 |
| P/E at the last close | 45.2× | 38.9× |
| Insider trades, last 12 months | sold $2.0 million | sold $3.0 million |
| Piotroski F-score | 4 of 9 | 6 of 9 |
Amounts in each company's own currency, US$ unless marked (a foreign company may report in another), each company's latest fiscal year from its 10-K, or 20-F or 40-F for a foreign company. Growth rates compare with the year before; the five-year rate is the average a year. Free cash flow is cash from operations minus capital spending; return on capital is after-tax operating income over the money invested in the business; P/E is the last close over the latest earnings per share. Banks are measured differently (return on equity, efficiency ratio), so some rows apply to one company only.
Ten years
Revenue
US$ billions, fiscal years
DoximityOmnicell
Operating margin
Percent of revenue
DoximityOmnicell
Free cash flow
US$ billions. Cash from operations minus capital expenditure.
DoximityOmnicell
Source: the companies' Form 10-K filings, from SEC EDGAR, and the last close. For information only, not investment advice: the figures describe results, not which company is the better investment. The Filing Desk is not affiliated with either company. Full figures on the Doximity and Omnicell pages.